Article:
Recombinant Human Platelet– Derived Growth Factor: A Systematic Review of Clinical Findings in Oral Regenerative Procedures
Summary:
The use of
recombinant human plateletderived
growth factor–BB (rhPDGF)
has received Food and Drug
Administration approval for the
treatment of periodontal and
orthopedic bone defects and dermal
wound healing. Many studies
have investigated its regenerative
potential in a variety of other oral
clinical indications. The aim of this
systematic review was to assess the
efficacy, safety, and clinical benefit
of recombinant human plateletderived
growth factor (rhPDGF) use
for alveolar bone and/or soft tissue
regeneration. Based on the
clinical evidence, rhPDGF is safe and
provides clinical benefits when used
in combination with bone allografts,
xenograft, or β-TCP for the treatment
of intrabony and furcation periodontal
defects and gingival recession or
when used with allografts or xenograft
for GBR and ARP.